Background: Syngeneic tumor models have proven to be one of the most robust model systems for cancer immunotherapy. However, in vitro screens that are frequently used in oncology to quickly identify cells, models, and PD effects for further study often fail in immuno-oncology, due to immunotherapeutics targeting the complex host immune system. Alternatively, an in vivo screen with a panel of models addresses many of these questions, e.g. PD and efficacy, but may be cost prohibitive. Material and methods: Leveraging in-house detailed profiling data on our syngeneic models, including efficacy benchmarking with aPD-1, aPD-L1 and aCTLA-4 antibodies, RNAseq data on tumor samples, and FACS analysis on both baseline and treatment response tumor samples, CrownBio recently launched a new service platform: MuScreen. MuScreen includes up to 20 well-characterized syngeneic models in a 3 month screening run. Both PD and efficacy may be determined in the run, allowing researchers to make decisions based on results observed from a large dataset. To address the cost issue, test agents from multiple clients are pooled together for each run (sharing vehicle and other common groups) providing a significant reduction in the number of animals used and the associated costs. Results: CrownBio has established the largest collection of syngeneic models with well-characterized immunotherapy data. In the first MuScreen run, we have generated new data on common IO agents, e.g. aPD-1 antibodies, with FACS analysis, IHC, and efficacy data. The first complete set of MuScreen data will be shown. Design parameters, such as starting tumor size, group size, of the MuScreen studies will be discussed. Conclusions: MuScreen is the first in vivo screening tool for cancer immunotherapeutics. It provides detailed response data on a panel of syngeneic models, therefore enabling decision making in a cost and time efficient manner.
Citation Format: Ying Jin, Lan Zhang, Juan Zhang, Eric Murphy, Zhongliang Li, Meng Qiao, Qian Shi. A panel of well characterized syngeneic models for in vivo screening analysis: MuScreenTM [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr B098.
- ©2016 American Association for Cancer Research.